<SEC-DOCUMENT>0001714899-25-000146.txt : 20250707
<SEC-HEADER>0001714899-25-000146.hdr.sgml : 20250707
<ACCEPTANCE-DATETIME>20250707080457
ACCESSION NUMBER:		0001714899-25-000146
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250707
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250707
DATE AS OF CHANGE:		20250707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		251107016

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8547

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20250707.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0ee53897-a921-4737-a8b0-89da63c9eebf,g:2de30e5e-3ad7-49eb-8324-d55a9224831b,d:584bc0185d0c43fa96e708e1ac4faeaa-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20250707</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20250707.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-07</xbrli:startDate><xbrli:endDate>2025-07-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i584bc0185d0c43fa96e708e1ac4faeaa_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 7, 2025</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">866-8547</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol (s) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:381.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:32pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    &#9744;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i584bc0185d0c43fa96e708e1ac4faeaa_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.01 &#160;&#160;&#160;&#160;Regulation FD Disclosure. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2025, Denali Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted and granted Priority Review of its Biologics License Application for tividenofusp alfa for the treatment of Hunter syndrome (MPS II). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Description</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="exhibit991pressrelease7720.htm">Press release dated July 7, 2025.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i584bc0185d0c43fa96e708e1ac4faeaa_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 7, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexander O. Schuth</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander O. Schuth, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating and Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991pressrelease7720.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7f22af54a45f472d9bb42a2622add982_1"></div><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  Exhibit 99.1</font></div><div><font><br></font></div></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tividenofusp alfa leads company&#8217;s broader TransportVehicle&#8482;-enabled pipeline</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SOUTH SAN FRANCISCO, Calif., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> July 7, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Denali Therapeutics Inc. (Nasdaq&#58; DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for tividenofusp alfa for the treatment of Hunter syndrome (mucopolysaccharidoses type II, or MPS II), a rare and progressive genetic disorder. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hunter syndrome is caused by a deficiency in the iduronate 2-sulfatase (IDS) enzyme, which is needed to break down complex sugars called glycosaminoglycans that build up in the brain and body, starting at a young age. Current therapies do not cross the blood-brain barrier and lack the potential to address the impact of the disease on cognitive abilities and behavior. Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy composed of IDS fused to Denali&#8217;s TransportVehicle&#8482; platform and is designed to deliver IDS into the brain and the body, aiming to treat neurological manifestations of the disease in addition to physical symptoms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We are grateful to the FDA for their recognition of the urgent need for new therapies that could offer a significant improvement in the treatment of Hunter syndrome, as reflected by their priority review designation for our Biologics License Application for tividenofusp alfa,&#8221; said Carole Ho, M.D., Chief Medical Officer and Head of Development of Denali Therapeutics. &#8220;If FDA-approved, tividenofusp alfa would mark the first significant advancement in nearly two decades for enzyme replacement therapy for individuals living with Hunter syndrome because of its potential for delivery to tissues throughout the brain and the body. This is also a pivotal milestone for our TransportVehicle platform, which continues to progress with the aim of treating a wide range of lysosomal storage diseases and neurodegenerative disorders.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BLA submission is supported by data from the open-label, single-arm Phase 1&#47;2 study of tividenofusp alfa in 47 participants with Hunter syndrome. Denali continues to prepare for a potential commercial launch in the U.S. and is conducting the ongoing Phase 2&#47;3 COMPASS study to support global regulatory approvals. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Tividenofusp Alfa</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tividenofusp alfa (DNL310) is composed of the iduronate 2-sulfatase (IDS) enzyme fused to Denali&#8217;s proprietary TransportVehicle&#8482; (TV) platform, designed to deliver IDS into the brain and the body, with the goal of addressing behavioral, cognitive, and physical symptoms of Hunter syndrome (MPS II). The U.S. Food and Drug Administration has granted Fast Track and Breakthrough Therapy designations to tividenofusp alfa for development in the treatment of MPS II. The European Medicines Agency has granted Priority Medicines designation to tividenofusp alfa.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2&#47;3 COMPASS study is enrolling participants with MPS II in North America, South America, and Europe to support global approval. Participants are randomized 2&#58;1 to receive either tividenofusp alfa or idursulfase, respectively. More information about the COMPASS study can be found </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">here</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tividenofusp alfa is an investigational therapeutic and has not been approved for use by any Health Authority.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#4f81bd;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Hunter Syndrome (MPS II)</font></div><div><font style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hunter syndrome, also known as MPS II, is a rare genetic lysosomal storage disease caused by mutations in the iduronate-2-sulfatase (IDS) gene. This results in a deficiency of the IDS enzyme, which is responsible for breaking down glycosaminoglycans (GAGs) such as heparan sulfate and dermatan sulfate. The accumulation of GAGs leads to progressive damage in multiple organs and tissues, including the brain. Symptoms of Hunter syndrome include developmental delays, cognitive decline, behavioral abnormalities, and physical complications such as joint stiffness, hearing loss, and organ dysfunction. Current standard-of-care enzyme replacement therapies do not cross the blood-brain barrier and therefore do not address the neurological symptoms of the disease. There is a significant unmet need for therapies that address both the central nervous system (CNS) and peripheral manifestations of Hunter syndrome.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the Denali TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Platform</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The blood-brain barrier (BBB) is essential in maintaining the brain&#8217;s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali&#8217;s TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated and three TV-enabled programs are currently in clinical development.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali Therapeutics</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics is a biotechnology company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.denalitherapeutics.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding plans, timelines, and expectations related to Denali's TransportVehicle&#8482; (TV) platform and its therapeutic and commercial potential&#59; plans, timelines, and expectations relating to tividenofusp alfa (DNL310), including the conduct of the ongoing Phase 2&#47;3 COMPASS study, the timing of the PDUFA action date and the likelihood of regulatory approval, and the timing and likelihood of commercial launch&#59; expectations for ongoing communications with the FDA&#59; the impact of any tividenofusp alfa approval on other TV-enabled programs&#59; tividenofusp alfa&#8217;s therapeutic potential&#59; and statements made by Denali&#8217;s Chief Medical Officer. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to&#58; risks that the PDUFA action date may be extended and the FDA may ultimately determine not to approve the BLA in its present form or at all&#59; risks arising from adverse economic conditions and their impact on Denali&#8217;s business and operations&#59; the possibility of events or changes that could lead to the termination of Denali&#8217;s collaboration agreements&#59; challenges associated with Denali&#8217;s transition to a late-stage clinical drug development company&#59; the ability of Denali and its collaborators to complete the development and, if approved, the commercialization of product candidates&#59; difficulties in patient enrollment for ongoing and future clinical trials&#59; reliance on third-party manufacturers and suppliers for clinical trial materials&#59; dependence on the successful development of Denali&#8217;s blood-brain barrier platform technology and related programs&#59; potential delays or failures in meeting expected clinical trial timelines&#59; the risk that promising preclinical profiles may not be replicated in clinical settings&#59; discrepancies between preclinical, early-stage, or preliminary clinical results and outcomes from later-stage trials&#59; the occurrence of significant adverse events or other undesirable side effects&#59; and the uncertainty surrounding regulatory approvals required for commercialization&#59; Denali&#8217;s ability to advance a pipeline of product candidates or develop commercially successful products&#59; developments relating to Denali's competitors and its industry, including competing product candidates and therapies&#59; Denali&#8217;s ability to obtain, maintain, or protect intellectual property rights related to its product candidates&#59; implementation of Denali&#8217;s strategic plans for its business, product candidates, and blood-brain barrier platform technology&#59; Denali's ability to obtain additional capital to finance its operations, as needed&#59; Denali's ability to accurately forecast future financial results in the current environment&#59; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and May 6, 2025, respectively, and Denali&#8217;s future reports to be filed with the SEC. Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. No Denali product candidates have been approved by any health authority for any use. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali&#8217;s expectations, except as required by law. </font></div><div><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laura Hansen, Ph.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hansen&#64;dnli.com</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(650) 452-2747</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rich Allan</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FGS Global </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rich.allan&#64;fgsglobal.com</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(503) 851-0807</font></div><div style="text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20250707.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0ee53897-a921-4737-a8b0-89da63c9eebf,g:2de30e5e-3ad7-49eb-8324-d55a9224831b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20250707" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20250707">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20250707_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20250707_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20250707_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0ee53897-a921-4737-a8b0-89da63c9eebf,g:2de30e5e-3ad7-49eb-8324-d55a9224831b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_680bba6c-4485-4584-a14a-468109718776_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_84349394-5a72-4a11-94f0-6dac36e1708d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b3171089-6a2b-417c-8914-3a1cfe0aa908_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_37528baa-a97f-4954-9548-475951a9adaf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b4050d50-8741-47a6-b8b6-255a6abcf324_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_37ec1786-7f42-4209-bfed-0073e482ebac_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a00bd4dc-28d0-4c48-a9d9-52ff47258138_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_16edf1dd-ac91-47fa-a2ce-0ecf4661341f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_5762f3fa-68b6-4921-89db-6656e1077c5b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f3bbffa4-2d58-4dba-9075-72ad6abf85c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a3f2d1da-d278-45ff-93bb-479e72bed560_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e2372991-7769-4923-bec4-ee24fd64dc06_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bab7f3bb-56e7-4ad4-8935-3ea20406ebe4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_59a146f1-3745-430a-bf3a-7f5a8a60e207_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_082438a7-862a-4ca5-8237-7715b5ecc6b9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_baa33316-566c-45ab-b770-ee76ce8f1cf3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c3a2f046-8eda-4f61-95a1-33810b2abc1d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c4434775-9170-455a-aa01-3ee40f18f321_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f6541503-42b6-4024-a8c5-1ca5ff1b8654_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_30b364e0-8cda-4f15-b1b3-5599f0c9dc3d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e89e49f4-423b-452b-9e58-c59a469cf947_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5a7bdfeb-79bd-4061-9d29-9a5db960e190_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20250707_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0ee53897-a921-4737-a8b0-89da63c9eebf,g:2de30e5e-3ad7-49eb-8324-d55a9224831b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20250707.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2bdeda0b-92a9-40bf-b51d-21281dab593e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_DocumentType_2bdeda0b-92a9-40bf-b51d-21281dab593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a3666132-7a4a-4d9c-919c-13083200f6ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_DocumentPeriodEndDate_a3666132-7a4a-4d9c-919c-13083200f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_580b1da4-1202-4f0f-889b-768c6f332463" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityRegistrantName_580b1da4-1202-4f0f-889b-768c6f332463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f40c4ff3-b401-4955-85c6-4a7102d62d10" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f40c4ff3-b401-4955-85c6-4a7102d62d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_28cff39e-4d8f-459a-9ab0-4bf18d3c0d82" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityFileNumber_28cff39e-4d8f-459a-9ab0-4bf18d3c0d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2d0127ff-aa57-4ee5-980d-970e605bb359" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityTaxIdentificationNumber_2d0127ff-aa57-4ee5-980d-970e605bb359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e2aed9ec-8f2a-4a0b-8f20-13bbf6911708" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityAddressAddressLine1_e2aed9ec-8f2a-4a0b-8f20-13bbf6911708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b80fd2fc-b64f-4ef5-872d-b5446f081224" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityAddressCityOrTown_b80fd2fc-b64f-4ef5-872d-b5446f081224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4810c9ee-5ccd-4041-82e3-f59327796504" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityAddressStateOrProvince_4810c9ee-5ccd-4041-82e3-f59327796504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f21feb99-b5ae-45dd-b6f3-78965c321adc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityAddressPostalZipCode_f21feb99-b5ae-45dd-b6f3-78965c321adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11ca6d1a-a860-42a3-b0a6-06e6f8151acd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_CityAreaCode_11ca6d1a-a860-42a3-b0a6-06e6f8151acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_791ee3f5-5d28-4488-8521-fd89a258374c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_LocalPhoneNumber_791ee3f5-5d28-4488-8521-fd89a258374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ddfad35b-af73-4071-a0c3-e193fdf25b35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_WrittenCommunications_ddfad35b-af73-4071-a0c3-e193fdf25b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_862afa1c-ef15-474b-a707-baa28a81fffc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_SolicitingMaterial_862afa1c-ef15-474b-a707-baa28a81fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_2a64b985-9dde-4ec0-a25f-41b15170ea34" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_PreCommencementTenderOffer_2a64b985-9dde-4ec0-a25f-41b15170ea34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ad283d10-c73a-41e7-8444-0906d0bf9266" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ad283d10-c73a-41e7-8444-0906d0bf9266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_579da5a5-e8e3-400d-9eaa-e2b402c9f525" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityEmergingGrowthCompany_579da5a5-e8e3-400d-9eaa-e2b402c9f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5056d043-94dc-421e-afe7-3501cc2eba5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_TradingSymbol_5056d043-94dc-421e-afe7-3501cc2eba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_57fb2f9d-ddea-41a7-b52f-9dc7cf9467a0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_SecurityExchangeName_57fb2f9d-ddea-41a7-b52f-9dc7cf9467a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_811e5314-0ee1-4daa-be47-6c4a220badef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_EntityCentralIndexKey_811e5314-0ee1-4daa-be47-6c4a220badef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_feb34147-05e1-4292-953f-d4292e77fa6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_AmendmentFlag_feb34147-05e1-4292-953f-d4292e77fa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3abff9d8-a850-4460-affc-ab487932bab1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a156ce71-cb2c-40bb-a417-dcf1b8e1e06f" xlink:to="loc_dei_Security12bTitle_3abff9d8-a850-4460-affc-ab487932bab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        #<     0   -P    !  .@ 0 #     0 !  "@
M @ $     0   <J@ P $     0   '0     _^T .%!H;W1O<VAO<" S+C
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MD?HY!9NHV]_S6U_QKXQ\57K:CXGU;4M1G8Y,MY<R2M^&YCC\*YFO2/ 'P?\
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M<D?$?P\1P1KVGX/_ &\QUV/[17_)>_&7_8R7W_HUJXWX;_\ )1O#W_8>T_\
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M_P"D[U_*Q'_JU^@KMPFS/.QVZ/N7_@G?_P G-6/_ &"-0_\ 18K^@:OY^?\
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M\],**** /YI?VO/^3E_&?_88/_HJ.O ]&_Y#%I_U]1?^ABO?/VO/^3E_&?\
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M_6#J/@CP;K%VVH:KI6FW,[XWS3VT4CMC@99D)/YU1_X5K\//^@'I'_@'!_\
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M.U32-*UNT-AK%M;W<)8,8KF-94R.AVN",_A13GRM,56'-%Q/Y)MZ^HK^A_\
M8%L[JS_9CT,74;Q^;->S1[U*[HWN'*L,]0>Q[U]*?\*U^'O_ $ ](_\  .#_
M .-UVD44<,:PPJJ(BA410 J@<  #@ 5M5K\RM8QH8;D=[CZ***YCJ"BBB@#^
M:O\ ;$MY[/\ :9\8+=(T9DU02H)!MW(\,95AGJ#V->!^&[>XO_$5A96*/--+
M>P1Q11#<[LS@ *!R2:_JOU?PEX6U^=;K7--L;R55V+)=6\<K!?0%U)Q5?3O
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MS__4_OPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*CF-FF120KAE/!(Y%?%GPY\._MZ?$GX>:;\2/#WQ"TP0ZG9B]MK.ZMHEDY)
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MIE*JM1TG=!11161H%%%% !1110 4444 ?__6_OPHHHH **** "BBB@ HHHH
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1LC4**** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20250707.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="dnli-20250707.htm">dnli-20250707.htm</File>
    <File>dnli-20250707.xsd</File>
    <File>dnli-20250707_lab.xml</File>
    <File>dnli-20250707_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dnli-20250707.htm": {
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20250707",
   "dts": {
    "inline": {
     "local": [
      "dnli-20250707.htm"
     ]
    },
    "schema": {
     "local": [
      "dnli-20250707.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20250707_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20250707_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20250707.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20250707.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001714899-25-000146-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-25-000146-xbrl.zip
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M\F\>@AZX[.D[;%O:!\VWSO?RJSJN[1/!Z)QRFZ5VK;JDVOM/6$&? [!=EZ/
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M?@?R 'F#6!->]_QTWJ&L5VF#,<@XK%ERO&?[_T>[Z W[!5^._@!02P,$%
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M;=NK_J]^S;XZHOM&=L-(=XHP3@0[O&W"_.1@-KN7(]4E?( XZ_[^^N'\D<D
ME2TQB)#L%J[;PC>'OMXLNJ&+LQK10*?[F[1W6SB>-\5F6\+NW#I!/)Z'JBQ(
M%UV:T[PS_9_["Q>?/=@F:!";?L87>.+A^L[*&&_@MH4JP/U<=[;*VC\:5'9*
MUW]=65H'97]V&:!8]G<]=4V;K&^7EJG,0\Z(=]P329TC5K*<!!^9T\" 9O'Q
MY#OG&_2^#TP#_G!5?UK@C3% 7'8'G3*R5^6)N7N%7N;W[C_Q"L<NN4,1+'7$
M<&LZMR-QB@7"&=<L6*>,@%%N?VGML==?1O8T^5F= B1<2G;F;/)/HOP8XH<1
MBZU->"/BUT49=E?'5&_V$:NVWH-R]V%!=^<SG'6$E"!<W$?EJY/K9];B @O]
MR'U$_!)248>W5?@!5^"E%5F6,<%);J4E,AA/#,,/)B@ND)3&#/83^D=F!S'
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M?Z_SI7C(CO3XV]];Q(N+OL#_HDQ&8N^U=*G\UP]WCQ_AJ=<O7^S#DZ22'$B
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MI.F'M!Z@3U&,4YIP0H_@"37 ^-CH''06*ET!H6%-CJ#^REB"QV0V061RVF"
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MW6!D)%05?)@<;&3+;[QT)VJ;.8!<?P#%<VK,X]F>V9)!^VC<DH/^VJJMV9?
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M-S W+FAT;5!+ 0(4 Q0    ( )M YUJ/]M)89 (  !<'   1
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@<V4W-S(P+FAT;5!+!08     !0 % % !  !B.      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>dnli-20250707_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20250707.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2025-07-07</startDate>
            <endDate>2025-07-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-07-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">866-8547</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
